Drugs / AG-920
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05501860 | Jul → Dec 2022 | — | American Genomics, LLC | Completed | No outcome recorded |
| Phase 3 | NCT05325853 | Apr → May 2022 | — | American Genomics, LLC | Completed | Met primary |
| Phase 3 | NCT04829344 | Mar → May 2021 | — | American Genomics, LLC | Completed | Met primary |
| Phase 3 | NCT04513652 | Sep 2020 | — | American Genomics, LLC | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AG-920 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05325853 ↗ |
| Route | Topical | “AG-920 Sterile Topical Ophthalmic Solution” NCT04513652 ↗ |